诱导一种调节性T细胞1型反应,可以减少阿波利波蛋白E-Knockout小鼠中动脉样硬化的发展
Ziad Mallat1, Andrea Gojova, Valérie Brun
1Institut National de la Santé et de la Recherche Médicale, INSERM U541, Institut Fédératif de Recherche Circulation Paris VII, Hôpital Lariboisière, Paris, France. mallat@larib.inserm.fr
Circulation
|August 13, 2003
概括
监管性T细胞1型 (Tr1) 的采用性转移抑制了T助手1型 (Th1) 反应. 这种免疫调节显著减少了小鼠实验性动脉样硬化发展和病变严重程度.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
- T细胞生物学T细胞生物学
背景情况:
- 辅助T型1 (Th1) 免疫反应与促进动脉样硬化有关.
- 调控性T细胞1型 (Tr1) 是一种具有潜在免疫抑制功能的新型T细胞亚型.
研究的目的:
- 调查Tr1细胞采用转移可以抑制Th1反应的假设.
- 为了确定Tr1细胞转移是否可以限制实验性动脉样硬化的发展.
主要方法:
- 卵蛋白 (OVA) 特定的Tr1细胞在实验室中被扩大,并通过收养转移到无脂蛋白E敲击小鼠中.
- 小鼠接受了OVA/完全弗洛恩德辅助剂 (CFA) 免疫接种,有或没有Tr1细胞.
- 通过测量OVA特异性IgG2a,干扰素-玛和互白素-10水平来评估Th1反应.
- 动脉样硬化病变的大小和斑块组成在9周后被分析.
主要成果:
- 治疗Tr1细胞显著降低了Th1反应,由OVA特异性IgG2a和干扰素-的降低以及增加的互白素-10证明.
- 在脏细胞中观察到明显的转向调节性免疫反应.
- 胸前大动脉和大动脉鼻腔中注意到动脉样损伤大小的显著减少.
- 接受Tr1治疗的小鼠在动脉样硬化斑块中表现出较低的巨细胞和T细胞积累.
结论:
- Tr1型调节性免疫反应有效地减少了实验性动脉样硬化.
- 通过调节免疫反应,Tr1细胞疗法具有治疗动脉样硬化的潜力.
相关概念视频
Desensitization and Tachyphylaxis
3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84


